Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
3,621 total articles
Edward Smolyansky, who holds roughly 10% of Lifeway Foods, sold 14,353 shares on March 19, 2026, at a weighted average price of $17.77, generating $255,052 in proceeds. The trade occurred while the stock was trading near its 52-week low. Lifeway also reported fourth-quarter 2025 results that missed analyst expectations on both EPS and revenue, alth…
Alignment Healthcare Chief Information Officer Robert L. Scavo sold 11,285 shares on March 18, 2026 at a weighted-average price of $17.84, raising $201,324 to satisfy tax withholding tied to vested restricted stock units. The sale was non-discretionary. The company recently reported robust fourth-quarter growth and faces a 13.2 million share second…
Ludmila Smolyansky sold 10,000 shares of Lifeway Foods Inc (NASDAQ:LWAY) on March 18, 2026, generating $187,399 from transactions executed between $18.42 and $19.34 per share. The sale arrives while the stock trades close to a 52-week low and after the company reported fourth-quarter 2025 results that fell short of analyst expectations on both EPS …
Alignment Healthcare Chief Human Resources Officer Andreas P. Wagner sold a combined 23,602 shares of the company's common stock in two transactions on March 18 and 19, 2026, generating approximately $425,476 in proceeds. One sale covered tax withholding on vested restricted stock units and was non-discretionary; the other was executed under a pre-…
Marcia Belvin, Senior Vice President and Chief Scientific Officer of CytomX Therapeutics, sold 31,492 shares on March 17, 2026, in a transaction disclosed on a Form 4. The sale, executed at $6.423 per share to meet tax obligations from restricted stock unit vesting, generated $202,273. CytomX is also pursuing a $250 million public offering as it ad…
Silver Lake Technology Investors V, L.P. and affiliated vehicles disposed of roughly $36.7 million of Dell Technologies Inc. Class C Common Stock on March 17, 2026, at prices between $153.14 and $155.00 per share. Dell’s shares have since traded up to $156.76, with InvestingPro data showing a 61.74% gain over the past year and a 25.08% return year-…
Christopher Ogden, chief financial officer of CytomX Therapeutics (CTMX), sold 19,323 shares on March 17, 2026, at $6.423 per share to cover tax liabilities tied to vesting restricted stock units. The transaction totaled $124,111 and followed by holdings of 296,948 shares, including 173,082 RSUs. Separately, CytomX has priced a public offering of 4…
Silver Lake Partners IV and affiliated investment vehicles sold 235,727 shares of Dell Technologies Class C common stock on March 17, 2026, for roughly $36.6 million. The transactions coincided with corporate conversions of Class B into Class C shares and follow a period of strong performance at Dell driven by AI server demand and related product e…
Robert Chatwani, President General Manager, Growth at DocuSign (DOCU), sold 17,492 shares on March 18, 2026, under a Rule 10b5-1 trading plan for total proceeds of about $803,042. DocuSign reported fiscal fourth-quarter 2026 EPS of $1.01 on revenue of $837 million, both above consensus. Multiple brokerages adjusted their price targets following the…
Aron Marquez, a director at Permian Resources Corp (NYSE: PR), reported the sale of 13,000 Class A shares in two transactions on March 17 and 18, 2026, totaling about $254,800. The trades were disclosed on a Form 4 and come while the stock sits near a 52-week high; the company also posted mixed fourth-quarter 2025 results with an EPS beat but a rev…
ContextLogic Holdings director Bobbili Raja acquired 29,000 shares of the company's common stock on March 17 for a total of $249,373, at per-share prices between $8.50 and $8.75. The shares now trade at $8.03. Raja’s disclosed ownership includes 350,000 shares held directly via an estate planning vehicle and an additional 18,269,534 shares held ind…
Castle Biosciences President and CEO Derek J. Maetzold sold a total of 19,300 shares of company common stock on March 17 and 18, 2026, in transactions filed on a Form 4. The trades, executed under a Rule 10b5-1 plan adopted in December 2025, generated $500,098 in proceeds. The company recently posted quarterly results that beat expectations on both…
Barry Ticho, chief medical officer at Stoke Therapeutics (STOK), sold 13,147 shares of common stock across March 17-19, 2026, generating about $413,019. The sales were conducted at prices between $31.2838 and $33.3754 per share and were reported on a Form 4 filing. Ticho also exercised options to purchase 1,365 shares at $2.19 on March 19. The tran…
Sarah Blake, SVP and Chief Accounting Officer at Venture Global, sold 200,000 Class A shares for $3.2 million on March 19, 2026, and concurrently exercised 200,000 options. The company reported a Q4 2025 EPS shortfall despite strong revenue growth and announced major project financing; analysts have adjusted price targets while an InvestingPro note…
Global Partners LP Chief Operating Officer Mark Romaine sold 2,223 common units of the partnership in two transactions on March 12 and March 13, 2026, totaling $105,751. The company reported mixed fourth-quarter 2025 results across its segments, and an analyst at Stifel raised the price target to $46 while keeping a Hold rating. InvestingPro data c…
Venture Global Chief Financial Officer Jonathan W. Thayer completed $50.5 million in Class A share sales and exercised more than 2.6 million options in mid-March 2026, while also receiving a new option grant. The transactions occurred as the stock trades well above the company’s assessed Fair Value by InvestingPro and after Venture Global reported …
Zscaler, Inc. Chief Product Officer Adam Geller sold 3,579 shares of company stock across two transactions on March 17 and 18, 2026, raising $554,031. One sale covered tax withholding from vested restricted stock units; the other was executed under a Rule 10b5-1 plan adopted in March 2025. The transactions leave Geller with 46,949 shares. The sales…
Keith D. Larson, General Counsel and Secretary of Venture Global, completed significant Class A Common Stock sales totaling roughly $76.8 million on March 18 and 19, 2026, while also acquiring shares by exercising options and receiving a new option grant. The insider moves coincide with a sharp year-to-date share price rise and come after a quarter…
Noble Corp plc Executive Vice President and CFO Richard B. Barker sold 150,000 A Ordinary Shares on March 18, 2026, generating roughly $6.9 million in proceeds through two transactions executed under a Rule 10b5-1 plan. The sale occurred while the stock sits close to its 52-week peak and after the company posted mixed fourth-quarter 2025 results an…
Noble Corp PLC President and CEO Robert W. Eifler sold 100,000 company shares on March 18, 2026, for $4.6 million in two tranches executed under a Rule 10b5-1 plan. The company posted mixed fourth-quarter 2025 results, with an EPS shortfall against expectations but revenue above forecasts. External analysis flags the stock as overvalued relative to…
Deborah Stein, a director at RB Global INC (NYSE: RBA), bought 400 shares on March 18, 2026, for $98.74 each, a total outlay of $39,496. The transaction raised her direct holdings to 1,400 shares. The purchase price exceeded the prevailing share price of $95.84, while InvestingPro’s Fair Value assessment indicates the stock remains undervalued. Sep…
Stoke Therapeutics Chief Financial Officer Thomas Leggett sold 5,378 shares of company stock on March 17 and 18, 2026, in a series of transactions that generated $147,144. The disposition was reported as an issuer-mandated sale to satisfy tax withholding tied to vested restricted stock units. The trades come amid mixed signals for the company: stro…
Paul A. Maleh, president and CEO of CRA International, sold 7,182 shares on March 17, 2026, for a total of $1.16 million under a Rule 10b5-1 trading plan. The company reported record revenue for the fourth quarter and full year of 2025, topping revenue estimates but narrowly missing EPS forecasts. CRAI shares traded near their 52-week low amid thos…
Jason Hoitt, chief patient officer at Stoke Therapeutics (NASDAQ: STOK), sold 3,712 shares of common stock on March 17-18, 2026 to satisfy tax withholding obligations tied to restricted stock unit vesting. The transactions totaled $119,310 and leave Hoitt with 10,276 shares. The company also disclosed executive compensation details and updated clin…
Jonathan Allan, General Counsel and Corporate Secretary of Stoke Therapeutics, sold 8,995 shares of company stock across transactions on March 17 and 18, 2026, generating approximately $285,900. The sales were disclosed as mandated transactions to satisfy tax withholding tied to restricted stock unit vesting and settlement. Separately, Stoke's boar…
